Short answer
Dyne Therapeutics, Inc. (DYN) filed an 8-K current report with the SEC on June 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Barry E. Greene elected independent Class I director through 2027 annual meeting.
Dyne Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Barry E. Greene elected independent Class I director through 2027 annual meeting
- New director receives option for 57,463 shares at $20.87 exercise price
- Option vests monthly over three years, with full acceleration upon change in control
- Annual compensation includes $45,000 cash, equity grants and expense reimbursement
- No committee assignment, related-party transactions or election arrangements disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dyne Therapeutics, Inc. 8-K filings
Get the next DYN 8-K as it lands
Follow DYN for push alerts, or ask the research agent what this filing means.